Article thumbnail

Biologics in the management of psoriasis

By Jennifer D Bahner, Lauren Y Cao and Neil J Korman

Abstract

Psoriasis is a chronic inflammatory systemic disease for which there exist topical, ultraviolet, systemic, and biologic treatments. Biologic agents selectively interfere with the immune mechanisms responsible for psoriasis. Etanercept, infliximab, and adalimumab target tumor necrosis factor-alpha and have demonstrated efficacy in the treatment of psoriasis and psoriatic arthritis. Alefacept and efalizumab target T lymphocytes, are effective in the treatment of psoriasis, but are not approved for psoriatic arthritis. Finally, ustekinumab and ABT-874 target interleukin-12 and interleukin-23, and they have demonstrated efficacy in the treatment of psoriasis. The objective of this review is to present efficacy and safety data from randomized controlled trials of the biologic agents in the treatment of psoriasis

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3047928
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2000). [No authors listed] Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep.
  2. (2008). [No authors listed] Trial watch: novel biologic for psoriasis shows superiority over current best-seller. Nat Rev Drug Discov.
  3. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis.
  4. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
  5. A human interleukin12/23 monoclonal antibody for the treatment of psoriasis.
  6. A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis.
  7. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
  8. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis.
  9. A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
  10. (2003). A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol.
  11. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease.
  12. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.
  13. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
  14. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
  15. (2005). Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus. Curr Pharm Des.
  16. Alefacept Clinical Study Group. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis.
  17. Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.
  18. (2003). Alefacept Clinical Study Group. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol.
  19. (2008). Alefacept in the treatment of psoriasis. Clin Dermatol.
  20. Alefacept package insert.
  21. (2003). An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol.
  22. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis.
  23. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther.
  24. Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking.
  25. (2006). Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence. BMC Dermatol.
  26. Binding and functional comparisons of two types of tumor necrosis factor antagonists.
  27. Case reports: practical experience with efalizumab in hand and foot psoriasis.
  28. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis.
  29. (2006). Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep.
  30. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study.
  31. (2006). CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderateto-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
  32. (2005). Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum.
  33. Clinical pharmacokinetics of tumor necrosis factor antagonists.
  34. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
  35. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.
  36. (1996). Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum.
  37. (2006). Consistency of infliximab response across subgroups of patients with psoriasis: integrated results from randomized controlled clinical trials. J Am Acad Dermatol.
  38. (1993). Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol.
  39. (1994). Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocytecolony stimulating factor levels in suction blister fluids and sera of psoriatic patients – relationships with disease severity. Clin Exp Dermatol.
  40. (2003). Current concepts and new developments in the treatment of psoriatic arthritis. Rheumatology
  41. (1996). Cytokine expression in psoriatic skin lesions during PUVA therapy. Arch Dermatol Res.
  42. (2008). Cytokines and anticytokines in psoriasis. Clin Chim Acta.
  43. De Kerkhof PC. The added therapeutic efficacy and safety of alefacept in combination with other (systemic) anti-psoriatics in refractory psoriasis.
  44. De Kerkhof PC. The effect of topical corticosteroids in combination with alefacept on circulating T-cell subsets in psoriasis.
  45. (2005). Disease Control and Prevention. Health, United States,
  46. (1984). double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum.
  47. (2006). EC; Alefacept in Psoriatic Arthritis Study Group. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum.
  48. (2004). Edwards CK 3rd. Biology of tumor necrosis factor-alpha- implications for psoriasis. Exp Dermatol.
  49. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
  50. Efalizumab for severe palmoplantar psoriasis: an open-label pilot trial in five patients.
  51. Efalizumab for the treatment of psoriatic arthritis.
  52. Efalizumab-induced guttate psoriasis. Successful management and re-treatment.
  53. (2006). Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Safety.
  54. (2008). Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res.
  55. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial.
  56. (2005). Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol.
  57. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.
  58. (2004). Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum.
  59. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial
  60. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial
  61. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION).
  62. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.
  63. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol. 2006;54(3 Suppl 2):S101–S111.
  64. Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy.
  65. (1994). Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol.
  66. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.
  67. Etanercept as monotherapy in patients with psoriasis.
  68. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial.
  69. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
  70. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database.
  71. Etanercept treatment for children and adolescents with plaque psoriasis.
  72. Expression of interleukin-12 is increased in psoriatic skin.
  73. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol.
  74. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
  75. Generalized pustular psoriasis following withdrawal of efalizumab.
  76. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
  77. Health Advisory: Updated Safety Information about Raptiva (efalizumab) http://www.fda.gov/cder/drug/advisory/efalizumab.htm
  78. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid.
  79. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1.
  80. Immune thrombocytopenia associated with efalizumab therapy for psoriasis.
  81. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
  82. (2005). Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol.
  83. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis.
  84. (2006). Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res.
  85. (2006). Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum.
  86. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
  87. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
  88. (2008). Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data. J Biol Regul Homeost Agents.
  89. interleukin-23, and psoriasis: current prospects.
  90. Interleukin-6 and tumour necrosis factor levels decrease in the suction blister fluids of psoriatic patients during effective therapy.
  91. International Psoriasis Council. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review.
  92. (2000). Interventions for psoriatic arthritis. Cochrane Database Syst Rev.
  93. Levels of response of psoriasis patients with different baseline characteristics treated with etanercept.
  94. (1993). Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin Exp Immunol.
  95. (2007). Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol.
  96. (2000). Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum.
  97. Methotrexate in psoriasis: consensus conference.
  98. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death.
  99. (1997). Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum.
  100. Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis.
  101. (2008). Palmoplantar pustular psoriasis: successful therapy with efalizumab after non-response to infliximab. Acta Derm Venereol.
  102. Pathogenesis and therapy of psoriasis.
  103. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
  104. Patterns of cytokine production in psoriatic synovium.
  105. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris.
  106. Pharmacokinetics of LFA3TIP (Amevive) in chronic plaque psoriasis patients during repeated once-weekly intravenous administration.
  107. Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis.
  108. (1996). Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin.
  109. Prevalence of cardiovascular risk factors in patients with psoriasis.
  110. (2006). Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol.
  111. (2004). Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp
  112. Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series.
  113. (1976). Psoriasis: a preliminary questionnaire study of sufferers’ subjective experience. Clin Exp Dermatol.
  114. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis.
  115. Quality of life of psoriasis patients.
  116. Rebound of psoriasis after efalizumab discontinuation, despite being on high-dose cyclosporine.
  117. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy.
  118. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
  119. (2008). Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol.
  120. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
  121. Safety and efficacy of subcutaneously administered efalizumab in adults with moderateto-severe hand and foot psoriasis: an open-label study.
  122. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
  123. Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. Part II.
  124. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity.
  125. (1997). Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents.
  126. Successful treatment of hand and foot psoriasis with efalizumab therapy.
  127. Successful treatment of recalcitrant palmoplantar psoriasis with efalizumab.
  128. The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms.
  129. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response.
  130. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients.
  131. The economic impact of psoriasis increases with psoriasis severity.
  132. The immunologic basis for the treatment of psoriasis with new biologic agents.
  133. The safety and efficacy of high-dose alefacept compared with a loading dose of alefacept in patients with chronic plaque psoriasis.
  134. (2005). The skinny on psoriasis and obesity. Arch Dermatol.
  135. (2006). Thio HB. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses.
  136. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an openlabel, multicenter, Phase IIIb study.
  137. Treatment of palmoplantar pustular psoriasis with efalizumab: a quick response with early recurrence.
  138. Treatment of psoriasis.
  139. Trivial or terrible? The psychosocial impact of psoriasis.
  140. Tumor necrosis factor antagonists in the therapy of psoriasis.